Chen, Jiaying <br/><br/>
Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.  [electronic resource] 

 -  Thyroid : official journal of the American Thyroid Association  09 2020 
 - 1245-1253 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-9077 
<br/><br/><label>Standard No.: </label>10.1089/thy.2019.0453  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers--blood<br/>Calcitonin--blood<br/>Carcinoma, Neuroendocrine--drug therapy<br/>Cell Differentiation<br/>China--epidemiology<br/>Female<br/>Humans<br/>Indoles--therapeutic use<br/>Iodine Radioisotopes--therapeutic use<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Pyrimidines--therapeutic use<br/>Receptors, Vascular Endothelial Growth Factor--metabolism<br/>Sulfonamides--therapeutic use<br/>Thyroid Neoplasms--drug therapy<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult